Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Subscribe To Our Newsletter & Stay Updated